Literature DB >> 10899226

Dopamine D(1) agonist activates temporal lobe structures in primates.

K J Black1, T Hershey, M H Gado, J S Perlmutter.   

Abstract

Changes in the function of dopamine D(1)-influenced neuronal pathways may be important to the pathophysiology of several human diseases. We recently developed methods for averaging functional imaging data across nonhuman primate subjects; in this study, we apply this method for the first time to map brain responses to experimental dopamine agonists in vivo. Here we report the use of positron emission tomography (PET) in seven normal baboons to measure the regional cerebral blood flow (rCBF) responses produced by an acute dose of the dopamine D(1) full agonist SKF82958. The most significant rCBF increases were in bilateral temporal lobe, including amygdala and superior temporal sulcus (6-17%, P < 0.001). Blood flow decreased in thalamus, pallidum, and pons (4-7%, P = 0.001). Furthermore the rCBF responses were dose-dependent and had a half-life of approximately 30 min, similar to that reported for the drug's antiparkinsonian effects. Absolute whole-brain blood flow did not change, suggesting that these local changes in rCBF reflect neuronal rather than direct vascular effects of the agonist. The prominent temporal lobe response to a D(1) agonist supports and extends our recent observations that levodopa produces prominent amygdala activation both in humans and in other primates. We speculate that levodopa may exert its known effects on mood in humans through increased amygdala activity, mediated in part by D(1) receptors.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10899226     DOI: 10.1152/jn.2000.84.1.549

Source DB:  PubMed          Journal:  J Neurophysiol        ISSN: 0022-3077            Impact factor:   2.714


  5 in total

1.  A possible substrate for dopamine-related changes in mood and behavior: prefrontal and limbic effects of a D3-preferring dopamine agonist.

Authors:  Kevin J Black; Tamara Hershey; Jonathan M Koller; Tom O Videen; Mark A Mintun; Joseph L Price; Joel S Perlmutter
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-13       Impact factor: 11.205

2.  Quantification of indirect pathway inhibition by the adenosine A2a antagonist SYN115 in Parkinson disease.

Authors:  Kevin J Black; Jonathan M Koller; Meghan C Campbell; Debra A Gusnard; Stephen I Bandak
Journal:  J Neurosci       Date:  2010-12-01       Impact factor: 6.167

3.  Prolactin and fMRI response to SKF38393 in the baboon.

Authors:  Brad Miller; Lauren A Marks; Jonathan M Koller; Blake J Newman; G Larry Bretthorst; Kevin J Black
Journal:  PeerJ       Date:  2013-10-29       Impact factor: 2.984

4.  Frequency-dependent gating of synaptic transmission and plasticity by dopamine.

Authors:  Hiroshi T Ito; Erin M Schuman
Journal:  Front Neural Circuits       Date:  2007-11-02       Impact factor: 3.492

5.  Rapid quantitative pharmacodynamic imaging by a novel method: theory, simulation testing and proof of principle.

Authors:  Kevin J Black; Jonathan M Koller; Brad D Miller
Journal:  PeerJ       Date:  2013-08-01       Impact factor: 2.984

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.